Pharma Focus Asia

Astellas Pharma and Kate Therapeutics Enter into Licence Agreement for KT430

Thursday, June 08, 2023

Astellas Pharma and Kate Therapeutics announced an exclusive licence agreement for the development and commercialisation of KT430.

Under the terms of the agreement, Astellas will provide an upfront payment to Kate Therapeutics. Additionally, Kate Therapeutics stands to receive milestone payments related to development, regulatory approvals, and commercial achievements, along with royalties based on global sales. 

As part of the agreement, Astellas will gain exclusive worldwide rights to develop, manufacture, and market KT430.

This agreement between Astellas and Kate Therapeutics aims to explore and advance the development of KT430 as a potential therapy for individuals diagnosed with X-linked myotubular myopathy (XLMTM). Moreover, this will allow Astellas and Kate Therapeutics to combine the expertise and resources to evaluate the therapeutic potential of KT430 in addressing the specific challenges faced by XLMTM patients.

KT430 is a preclinical next-generation investigational gene therapy that aims to treat X-linked myotubular myopathy (XLMTM). XLMTM is indeed a serious, life-threatening, and rare neuromuscular disease characterised by extreme muscle weakness, respiratory failure, and an increased risk of early death.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024